Easton, lives with pLGG.
Our comprehensive offerings help you support your patients
and their families throughout their
treatment journey.
We help patients and their families understand their benefits and obtain insurance coverage.
These programs help eligible patients pay for their medicine.
A dedicated point of contact that works alongside you and your patients throughout the insurance and treatment process.
We work with our Specialty Pharmacy partners to ship your patients’ medicine directly to their homes.
Hear one family share how EveryDay Support helped throughout their treatment journey.
pLGG=pediatric low-grade glioma.
You are being directed to a website with specific treatment options from Day One Biopharmaceuticals.
Would you like to proceed?
Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib) Copay Program (the “Program”) is available only for patients with commercial insurance with a valid prescription residing in the United States or a U.S. Territory, and is void where prohibited by law. The patient or their legal representative must be 18 years of age or older. Patients using Medicare (including Medicare Part D), Medicaid, Medigap, Veterans Affairs, Department of Defense, TRICARE, Children’s Health Insurance Program, or any other federal or state government program to pay in whole or in part for their OJEMDA treatment are not eligible to participate. Patient must have commercial health insurance that covers medication costs for OJEMDA, but not the full cost to the patient. Patient may not seek reimbursement for the value received from this program or cost of the prescription from other parties, including any health insurance program or plan (whether private or public), flexible spending account, or health care savings account. The Program is not transferable or substitutable and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer. The Program offer may not be sold, purchased, traded, or counterfeited.
The value of this program is exclusively for the benefit of enrolled patients and is intended to be credited toward patient out-of-pocket obligations, including applicable co-payments, co-insurance, and deductibles for OJEMDA, up to an established maximum amount per calendar year. It does not assist with the cost of other medications or office visit fees. After reaching the maximum Program benefit, the patient will be responsible for any remaining out-of-pocket costs for the medication incurred during that calendar year. The maximum Program benefit is provided annually, and it expires at the end of the calendar year and will reset every January 1st. Eligible patients will be automatically re-enrolled in the Program on an annual basis if the patient continues to meet all eligibility requirements set forth by the Program. Program participants are required to immediately inform EveryDay Support From Day One™ of insurance changes or if the patient is no longer eligible to receive Program benefits.
The Program may modify the benefit amount, unilaterally determined by Day One Biopharmaceuticals in its sole discretion, to satisfy the out-of-pocket cost sharing requirement for any patient whose insurance plan or insurance plan agent (including, but not limited to, a Pharmacy Benefit Manager (PBM)) requires enrollment in the Program as a condition of the insurance plan or PBM waiving some or all of an otherwise applicable patient out-of-pocket cost sharing amount. These programs are often referred to as co-pay maximizer programs. If you believe your insurance plan may have such limitations, or if you have any other questions about the terms of this Program, please contact EveryDay Support at 855-329-1246 (855-DAY1-BIO).
Day One Biopharmaceuticals reserves the right to rescind, revoke or amend this offer, eligibility, and terms of use at any time without notice.
